PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

• Status: Completed
• Trial end date: 2022-10-05
• Target enrollment: 0
• Participant gender: Male

Summary

The overall goal is to provide an innovative approach to restage patients with biochemical recurrence of prostate cancer by using hybrid PET/MR with innovative radiotracers (68Ga-PSMA and 68Ga-RM2)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IRCCS San Raffaele
• Treatments: Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

• Patients with histological proven diagnosis of prostate cancer.

• Patients treated with radical therapy (RP o EBRT, with or without further adjuvant therapies), who present rising serum PSA values ≥ 0.2 ng/mL.

• Age ≥ 18 years-old.

• Willing to provide a signed informed consent.

Exclusion Criteria:

• Age < 18 years-old.

• Previous and/or concomitant androgen deprivation therapy will be excluded.

• Any additional medical condition that may significantly interfere with study compliance.

• Contraindications to MR study (i.e. Pacemaker